Posts by: Kevin Perez

Kevin Perez

Kevin Perez holds a MS in Computer Science from New York University (NYU) and a MS in Biomedical Sciences from Paris Descartes University. He is interested in biomedical data analysis, and bringing the latest biomedical research news to patients.

September 14, 2017September 14, 2017

Jazz Partners with ImmunoGen to Develop Antibody-Drug Conjugate for AML, Other Blood Diseases

News

Jazz Pharmaceuticals and ImmunoGen have entered a partnership to advance two antibody-drug conjugates — IMGN779 and IMGN632 — for the treatment of acute myeloid leukemia (AML) and other blood-related disorders. The drugs are CD33 and CD123 antibodies, ... Read more

August 30, 2017August 30, 2017

FDA to Review Gazyva as First-Line Treatment for Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental biologics license application (sBLA) seeking the approval of Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone, for patients with previously untreated ... Read more

August 15, 2017August 15, 2017

New Combo Treatment for DLBCL, R-Chop Plus Acalabrutinib, Being Tested in UK

News

The University of Southampton in Britain is leading a Phase 1/2 clinical trial to test whether adding acalabrutinib to R-CHOP can improve outcomes for patients with diffuse large B-cell lymphoma (DLBCL). ... Read more